Cerebrolysin vs Dihexa
A side-by-side research comparison of Cerebrolysin and Dihexa across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Cerebrolysin | Dihexa |
|---|---|---|
| Full name | Cerebrolysin (Brain-Derived Peptide Preparation) | Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Investigational | Research compound |
| Mechanism | Contains fragments mimicking NGF, BDNF, GDNF, CNTF. Enhances synaptic plasticity, promotes neuronal sprouting, reduces amyloid-beta, and stabilizes calcium homeostasis. | Allosteric potentiator of HGF/c-Met signaling driving synaptogenesis, dendritic spine formation, and neuronal survival in hippocampal circuits. |
| Molecular weight | <10,000 Da (peptide fraction) | 507.6 Da |
| Half-life | 4-6 hours | 6-12 hours |
| Bioavailability | High (IM/IV) | Moderate (oral/SubQ) |
| Typical dose | 5-30 mL | 10-20 mg (oral) or 2-5 mg (SubQ) |
| Frequency | Daily for 10-20 days | Daily |
| Route | Intramuscular or IV | Oral or Subcutaneous |
Cerebrolysin reported benefits
- Neurotrophic support
- Stroke recovery
- Memory improvement
- Neuroprotection
- Synaptic plasticity
- Approved in 40+ countries
Dihexa reported benefits
- Dramatic synaptogenesis
- Memory improvement
- Cognitive restoration potential
- Dendritic spine growth
- HGF/c-Met activation
Related comparisons
Research and educational reference only. Not medical advice.